Versuchen GOLD - Frei
The ESRD crisis in Singapore
BioSpectrum Asia
|December 2020
In Singapore – where the crude incidence rate of late-stage chronic kidney disease has been rising – there are more people in the country, who must be especially concerned about maintaining social distancing. This is a particular conundrum for ESRD patients, who need to visit dialysis centres for treatment.
-
The COVID-19 pandemic is an unprecedented global emergency that – at the time of writing – has infected over 40 million people worldwide and claimed the lives of over a million people. Even though primarily regarded as a respiratory virus, more evidence is emerging that COVID-19 can affect multiple organs in the body, especially the immune and haematologic systems. This makes it even more dangerous to patients suffering from chronic diseases, particularly end-stage renal disease (ESRD) sufferers, who can be considered immunocompromised and may have multiple comorbidities.
In Singapore – where the crude incidence rate of late-stage chronic kidney disease has been rising – there are more people in the country, who must be especially concerned about maintaining social distancing. This is a particular conundrum for ESRD patients, who need to visit dialysis centres for treatment.
Dangerous to ESRD patients
When transmitted, the COVID-19 coronavirus enters the body through the respiratory system and begins to attack the lungs. From there, if not treated, it can attack other organs such as the kidneys, evidenced by a US study that found nearly a third of COVID-19 patients in intensive care developed acute kidney injury (AKI), with 15 per cent of those requiring dialysis.
Also, existing AKI sufferers who contracted COVID-19 were reported as being five times more likely to die from the virus – placing ESRD patients firmly in the ‘at-risk group’ as AKI frequently leads to ESRD. It therefore comes as little surprise that dialysis machines are as high in demand at hospitals as ventilator machines. This is because kidney failure incidences and AKI in COVID-19 patients are soaring – with an estimated 20 to 40 per cent of ICU patients in the US needing emergency dialysis.
Diese Geschichte stammt aus der December 2020-Ausgabe von BioSpectrum Asia.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON BioSpectrum Asia
BioSpectrum Asia
UK transforms mental healthcare with new strategy
Frontline workers, clinicians and mental health experts are being invited to share their views on how to transform mental healthcare for children and adults in England, as the government launches a call for evidence to shape its once-in-a-generation crossgovernment mental health strategy.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Australia Budget 2026-27: Investing in Care, Health and Innovation.
The Australian Federal Budget 2026-27, presented by the Albanese Government, places strong emphasis on healthcare, aged care, T disability services, research, innovation and social equality.
4 mins
BioSpectrum Asia June 2026
BioSpectrum Asia
Gavi proposes new incentives for advancing vaccine manufacturing in Africa
With Gavi's African Vaccine Manufacturing Accelerator (AVMA) expected to make its first cash disbursement to an African vaccine manufacturer in the second half of 2026, Gavi, the Vaccine Alliance has proposed further measures totaling $189 million of additional investment to further aid development of Africa's vaccine manufacturing sector.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
New WHO online course strengthens good practices in clinical trials
High-quality clinical trials are essential for generating reliable evidence to inform health policy, clinical practice and public trust in science.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
World Bank approves $225 M to improve healthcare in Côte d'Ivoire
The World Bank has approved $225 million in financing to help Côte d'Ivoire improve the delivery of quality health, nutrition, and early childhood development services for millions of people, particularly for women, children, and vulnerable households.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Nona Biosciences appoints Dr Josh Xiao as CSO
Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, has announced the appointment of Dr Josh Xiao as Chief Scientific Officer (CSO). Dr Xiao will be based in both the US and China and report directly to Dr Di Hong, Chief Executive Officer of Nona Biosciences.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Korea lays focus on stabilising medical product supply
The Ministry of Health and Welfare (MoHW), South Korea government, recently held its 7th meeting with healthcare and pharmaceutical associations, bringing together the Ministry of Trade, Industry and Resources (MOTIR), and the Ministry of Food and Drug Safety (MFDS).
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Formosa Pharma partners with SERI to advance novel ophthalmic formulations for corneal diseases
Taiwan-based Formosa Pharmaceuticals, Inc. and the Singapore Eye Research Institute (SERI) have announced a strategic research collaboration to develop next-generation ophthalmic formulations.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Academy of Digital Health Sciences launches two new courses in AI
Academy of Digital Health Sciences (ADHS), based in India, has announced the launch of its landmark 'AI for All' Mission, a bold, mission-driven programme designed to democratise artificial intelligence (AI) across global healthcare systems.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
AstraZeneca Korea names Ohad Goldberg as new Country President
AstraZeneca Korea has appointed Ohad Goldberg, former President of AstraZeneca Israel, as its new Country President, effective May 1.
1 min
BioSpectrum Asia June 2026
Translate
Change font size
